Whole Body PET-MRI in Paediatric and Adolescent Lymphoma
NCT ID: NCT02935348
Last Updated: 2016-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
25 participants
OBSERVATIONAL
2014-02-28
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Investigators want to investigate if a combined PET-MRI scan could give the same information.
Children who join our study will have an extra scan twice during their treatment
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MELT - MRI Evaluation of Lymphoma Treatment
NCT01459224
Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors
NCT00001301
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma
NCT05481437
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
NCT00685997
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
NCT00188149
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Investigators want to investigate if a combined PET-MRI scan could give the same information.
Children who join our study will have an extra scan twice during their treatment
Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Whole Body MRI
Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female participants
3. Age 0-20 years inclusive
4. Entered into the EuroNet PHL-C1 trial, LP1 trial or successor Euronet trials, including Euronet PHL C2 due to open from 2013 onwards or planned to receive chemotherapy regimens of said trials without being formally entered into the trial.
5. Participant/Guardian/Parental written informed consent
Exclusion Criteria
2. Participants who are pregnant or nursing
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Humphries
Role: PRINCIPAL_INVESTIGATOR
UCL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Medical Imaging
London, London, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13/0268
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.